[The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
The use of beta-interferons for immunomodulating treatment of multiple sclerosis (MS) in children is rstudied. We present results of the prospective study of 22 children, aged 13-17 years, with MS treated with beta-interferon-1b (betaferon) during 2-15 (mean 10,72) months. High efficacy and good tolerability of beta-interferon-1b is demonstrated.